Chronic treatment with CP-55,940 regulates corticotropin releasing factor and proopiomelanocortin gene expression in the hypothalamus and pituitary gland of the rat.
The purpose of the present study was to explore the molecular mechanisms by which the cannabinoid system may interact with the hypothalamic-pituitary adrenal axis and the proopiomelanocortin opioid system. To this aim and by using in situ hybridization histochemistry, the effects of chronic (18 days) administration with the synthetic cannabinoid receptor agonist [(-)-cis-3-[2-hydroxy-4-(1,1,-dimethylheptyl)-phenyl]-trans-4(-3-h ydroxypropyl)cyclohexanol)], CP-55,940 (1 mg/kg/day; i.p.) on corticotropin releasing factor and proopiomelanocortin gene expression were examined in the paraventricular and arcuate nuclei of the hypothalamus and anterior and intermediate lobes of the pituitary gland in the rat. Chronic administration with CP-55,940 increased corticotropin releasing factor mRNA levels (41%) in the paraventricular nucleus and proopiomelanocortin mRNA levels in the arcuate nucleus (25%) and anterior lobe of the pituitary (30%), but decreased (28%) of proopiomelanocortin transcript amounts in the intermediate lobe of the pituitary. These results revealed that chronic cannabinoid administration enhances corticotropin releasing factor and proopiomelanocortin gene expression in the hypothalamus and anterior pituitary, a process that may be considered as part of a molecular integrative response to the stress associated to cannabinoid drug abuse.